A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
15 October, 2024
Diversity, equity and inclusion at heart of TROG work
15 October 2024: TROG Cancer Research has made a
1 October, 2024
A plan for the future of cancer research
12 September 2024: TROG Cancer Research has outlined how
